These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18792067)

  • 1. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.
    Suardi N; Capitanio U; Chun FK; Graefen M; Perrotte P; Schlomm T; Haese A; Huland H; Erbersdobler A; Montorsi F; Karakiewicz PI
    Cancer; 2008 Oct; 113(8):2068-72. PubMed ID: 18792067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer.
    Suardi N; Briganti A; Gallina A; Salonia A; Karakiewicz PI; Capitanio U; Freschi M; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2010 Jun; 105(11):1548-52. PubMed ID: 19912205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients.
    Suardi N; Gallina A; Capitanio U; Salonia A; Lughezzani G; Freschi M; Mottrie A; Rigatti P; Montorsi F; Briganti A
    Cancer; 2012 Feb; 118(4):973-80. PubMed ID: 21751185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological outcomes of candidates for active surveillance of prostate cancer.
    Conti SL; Dall'era M; Fradet V; Cowan JE; Simko J; Carroll PR
    J Urol; 2009 Apr; 181(4):1628-33; discussion 1633-4. PubMed ID: 19233388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary evaluation of the D'amico risk classification of prostate cancer.
    Hernandez DJ; Nielsen ME; Han M; Partin AW
    Urology; 2007 Nov; 70(5):931-5. PubMed ID: 18068450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
    Chun FK; Suardi N; Capitanio U; Jeldres C; Ahyai S; Graefen M; Haese A; Steuber T; Erbersdobler A; Montorsi F; Huland H; Karakiewicz PI
    Eur Urol; 2009 Mar; 55(3):617-28-6. PubMed ID: 18499335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
    Jeldres C; Suardi N; Walz J; Hutterer GC; Ahyai S; Lattouf JB; Haese A; Graefen M; Erbersdobler A; Heinzer H; Huland H; Karakiewicz PI
    Eur Urol; 2008 Dec; 54(6):1306-13. PubMed ID: 18083294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.
    Gallina A; Chun FK; Suardi N; Eastham JA; Perrotte P; Graefen M; Hutterer G; Huland H; Klein EA; Reuther A; Montorsi F; Briganti A; Shariat SF; Roehrborn CG; de la Taille A; Salomon L; Karakiewicz PI
    BJU Int; 2008 Jun; 101(12):1513-8. PubMed ID: 18422773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
    Sankin A; Tareen B; Lepor H
    Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?
    Pepe P; Fraggetta F; Galia A; Grasso G; Piccolo S; Aragona F
    Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.
    Miyamoto H; Hernandez DJ; Epstein JI
    Hum Pathol; 2009 Dec; 40(12):1693-8. PubMed ID: 19683331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating rates of true high-grade disease in the prostate cancer prevention trial.
    Pinsky P; Parnes H; Ford L
    Cancer Prev Res (Phila); 2008 Aug; 1(3):182-6. PubMed ID: 19138954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Permanent prostate brachytherapy: pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy.
    Sengupta S; Davis BJ; Mynderse LA; Sebo TJ; Cheville JC; Lohse CM; Hillman DW; Haddock MG; Wilson TM
    Urology; 2006 Oct; 68(4):810-4. PubMed ID: 17070358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort.
    Tareen B; Sankin A; Godoy G; Temkin S; Lepor H; Taneja SS
    Urology; 2009 Feb; 73(2):351-4; discussion 354-5. PubMed ID: 19038430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.